Hoekstra-van Dalen RA, Cillessen JP, Kappelle LJ, van Gijn J. Cerebral infarcts associated with migraine: clinical features, risk factors and follow- up. J Neurol. 1996;243:511 515. doi: 10.1007/BF00886872 642. Rothrock J, North J, Madden K, Lyden P, Fleck P, Dittrich H. Migraine and migrainous stroke: risk factors and prognosis. Neurology. 1993;43:2473 643. Kellner-Weldon F, El-Koussy M, Jung S, Jossen M, Klinger-Gratz PP, Wiest R. Cerebellar hypoperfusion in migraine attack: incidence and significance. AJNR Am J Neuroradiol. 2018;39:435 440. doi: 10.3174/ajnr.A5508 644. Sheikh HU, Pavlovic J, Loder E, Burch R. Risk of stroke associated with use of estrogen containing contraceptives in women with migraine: a sys- tematic review. Headache. 2018;58:5 21. doi: 10.1111/head.13229 645. Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic re- view of observational studies. Cephalalgia. 2015;35:118 131. doi: 646. Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with cal- citonin gene-related peptide inhibitor therapy for migraine: a case re- port. J Stroke Cerebrovasc Dis. 2019;28:104286. doi: 10.1016/j. 647. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes. 2019;5:145 152. doi: 10.1093/ehjqcco/qcy040 648. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial. Am J Med. 2017;130:1440 1448.e1. 649. 